It is reported that the end-user developed redness to the left lower quadrant (llq) of abdominal skin after one (1) to three (3) days of use.This redness is described as being one half inch (1/2") encircling the retracted stoma associated with end-user's surgical procedure in march; end-user is unable to visualize stoma due to depth of retraction.It is further reported that end-user sought treatment in the emergency room (er) approximately 105 weeks ago, and then consulted the family physician who administered cipro, flagyl and a narcotic (name unknown) to treat affected site.
|
Based on the available information, this event is deemed to be a serious injury.It is reported that skincare is performed as follows: currently using zest soap and performing crusting techniques/procedures.It is further reported that end-user was advised to use a non-residue soap; to re-size barrier as current opening precut to 35 mm and stoma opening is 25mm.Lastly, samples sent to end-user.No additional patient/event details have been provided to date.A return sample for evaluation is not expected should additional information become available, a follow-up report will be submitted.Convatec will continue to track and monitor such complaints according to convatec inc's complaint handling and capa procedures.
|
The product associated with batch 3g01355 was made according to specification.After detailed batch review, no discrepancies (includes non-conformances/deviations) were found.This complaint is not associated with a product malfunction.The complaint/incidence data-post market data analysis (trend analysis), clinical review, root cause analysis and risk assessment indicate a consistent rate of complaints as a result of skin complications which are caused by a variety of external factors not related to the design, materials, and/or processes of the product.No further actions are required, and this complaint will be closed.Product monitoring reviews will monitor for product trends if this issue were to reoccur.(b)(4).No additional patient/event details have been provided to date.Should additional information become available a follow-up report will be submitted.Reported to the fda on march 14, 2016.(b)(4).
|